LONDON – The UK's golden triangle of biotech centered on London, Cambridge and Oxford is transitioning into a supercluster, as it leaves the rest of the country behind in terms of its percentage share of fundraising. (BioWorld International)

Advanced Accelerator Applications SA (AAA) closed a €40 million (US$57.4 million) funding round that will enable the company to move its lead drug candidate Lutathera (lutate; 177Lutetium DOTA0-Tyr3-Octreotate) into pivotal trials in cancer later this year and to complete the acquisition of an as yet undisclosed firm that is developing a drug for ovarian cancer. (BioWorld International)